Evogene Ltd. (NASDAQ:EVGN – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.17 and traded as low as $2.31. Evogene shares last traded at $2.40, with a volume of 28,936 shares.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on EVGN shares. Lake Street Capital dropped their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a report on Friday, August 23rd. StockNews.com initiated coverage on Evogene in a research note on Friday. They issued a “sell” rating for the company.
View Our Latest Research Report on Evogene
Evogene Price Performance
Evogene (NASDAQ:EVGN – Get Free Report) last posted its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The company had revenue of $0.91 million during the quarter.
Institutional Investors Weigh In On Evogene
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
See Also
- Five stocks we like better than Evogene
- How Technical Indicators Can Help You Find Oversold Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Stocks to Consider Buying in October
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Calculate Return on Investment (ROI)
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.